Gerresheimer, a partner to the pharma and healthcare industry, increased revenues and net income in Q3 of this year.
The company expects revenue growth of 5% to 6% on a like-for-like exchange rate basis for financial year 2013.
Revenues increased in Q3 of financial year 2013 (with an FY from 1st December to 30th November) by 1.8% to €316.9m. Excluding exchange rate effects, revenues grew by a substantial 4.5% compared with the prior-year quarter.
The pharmaceutical glass and pharmaceutical plastic systems businesses contributed notably to this growth.
The Company generated adjusted EBITDA of €61.6m in Q3 of 2013, exactly the same figure as a year earlier. The adjusted EBITDA margin was 19.4%, slightly below the 19.8% margin in the prior-year period.
Net income for Q3 came to €19.5m, 31.8% more than the prior-year quarter (€14.8m).
From the beginning of the new financial year on 1st December 2013, the Company will be managed through three divisions: Plastics and Devices, Primary Packaging Glass and Life Science Research. The divisions will continue to operate under their existing structure until November 30, 2013.
